Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 17 | 2025Bayer’s Finerenone Under Priority Review; Dexcom Receives FDA Warning; Zealand Completes Petrelintide Ph2b Enrollment; vTv Announces Clinical Hold Lift; Entera/OPKO Advance Oral AOM to ClinicPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 17 | 2025Obesity Spotlight: Can BI Step Outside of Lilly's Shadow?Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 14 | 2025Altimmune R&D Day 2025; Sagimet Q4 ‘24 Earnings Update; Ascletis Ph1b Data Readout; Fauna Bio Series A for HFpEFPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA + Basal, Other, Topics Mar 12 | 2025Roche is a Zeal-ot for PetrelintidePurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 11 | 2025Obesity Compounders Take a Hit; Viking Signs Manufacturing Deal; Roche Hires Novo Exec; Halia Receives Novo’s Golden TicketPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics Mar 10 | 2025Cagrisema T2DM + Obesity Ph3 Results; BI Discontinues MASH Asset; Mineralys Releases New HTN Results; Insulet SmartAdjust 2.0 Trial ObservedPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 10 | 2025Obesity Spotlight: Zealand’s Path to Find a PartnerPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 06 | 2025Amgen Initiates Ph3 MariTide Trials; LifeMD and Teladoc Integrate with LillyDirect; Arrowhead Preclinical Obesity DataPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 06 | 2025Novo Launches NovoCare DTP Platform; Lilly Manufacturing Pitches from States and Initiates TRIUMPH-6Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 04 | 2025New Lilly TV Ad; Novo Updates Ozempic Promo Campaign; Senseonics, Fractyl, and Esperion Q4 ‘24 Earnings UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 04 | 2025AbbVie Enters Obesity Race; Novo Initiates New Drug Development AI Partnership; Biocon Launches Generic Liraglutide in UKPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 28 | 2025Tandem, Altimmune, MannKind, Silence, and Viatris Q4 ’24 Earnings; Zevra Sells PRV; TIXiMED Ph1 TIX100 Trial UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Feb 27 | 2025Madrigal and NewAmsterdam Q4 ’24 Earnings; Lilly Manufacturing Expansion and Acquisition Update; New Eversense 365 Platform Integration Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Feb 25 | 2025Lilly Doubles Down on LillyDirect Program; Tandem AID Algorithm Cleared for T2DM; Compounders Sue FDA… Again; Lilly Acquires FXR Program; Terns Development UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal, Other, SGLT2i, Topics Feb 25 | 2025Lilly Stockpiles Orfoglipron; February CHMP Agenda ObservedPurchase Blast
$599
Posted in: Other, Topics Feb 25 | 2025Coming Soon: FENIX Obesity Spotlight SeriesPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 21 | 2025Sema Shortage Resolved; Pfizer/Viking M&A Rumor; Insulet Q4 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Feb 20 | 2025Zealand FY Q4 ‘24 Earnings; Steve Pacelli Leaves DexcomPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Feb 19 | 2025New Tandem AID Algorithm TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 18 | 2025Medtronic CY Q4 ’24 (FY Q3 ‘25) Earnings; FDA Approves Biosimilar Novolog; Allurion Balloon + GLP-1RA; Ph2 Oral VK2735 Trial ObservedPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
